Background {#Sec1}
==========

Cerebral metastases are an upcoming challenge for the oncological community as the life expectancy of brain cancer patients improves and, as a consequence, the possibility of cerebral metastasis increases \[[@CR1]--[@CR3]\]. Moreover, neurological integrity and functional status is becoming an important outcome parameter, as brain cancer develops into a more chronic disease \[[@CR4]--[@CR6]\]. The mainstays of brain metastases treatment are microsurgical resection or different radiotherapy modalities, as most systemic therapeutics are efficacious treatments for cerebral metastases.

Randomized trials have demonstrated that surgical resection or radiosurgery of cerebral metastases (single or limited number), followed by postoperative whole brain irradiation (WBI) results in a mean progression-free survival of 4.6-months over each modality alone and a significant reduction by 30% in local recurrence rates \[[@CR7]\]. However, WBI did not influence overall survival or survival with functional independence \[[@CR7], [@CR8]\]. In addition, WBI had an unfavorable outcome with long-term quality of life, as well as on the neurological and especially cognitive functions of patients. Therefore, new radiotherapy modalities like radiosurgery and stereotactic radiotherapy have been adopted, with both sharing a restriction of treatment to only the tumor site, which results in no prophylactic effect for any new brain metastases \[[@CR7]\].

Microsurgical resection (MSR) and stereotactic radiotherapy/radiosurgery (SRT/SRS) become thereafter two competitive modalities in the treatment of cerebral metastasis with distinct advantages. The stereotactic radiotherapy/radiosurgery was advocated for the treatment of oligometastatic cases (≤ 3) and/or deeply situated metastases because of its less invasive character \[[@CR9]\] and microsurgery was suggested for single and more superficially situated metastases to reduce local mass effect with faster tumor edema control \[[@CR10]\].

Both modalities attempt to protect or improve the functionality/neurological integrity, for microsurgery by reducing the mass effect and edema in the affected but non-malignant region of the brain, as well as stereotactic radiotherapy by reducing normal tissue radiation dose. The Rolandic, or central/motor cortex area, is a suitable site to investigate the advantages and disadvantages in regards to functional outcome from microsurgery or radiation treatments, where outcomes can be assessed with standard clinical rating scales like the British Medical Research Council (BMRC) scale for motor disability \[[@CR11], [@CR12]\].

Some studies have revealed that both microsurgery \[[@CR13], [@CR14]\] and radiosurgery/stereotactic radiotherapy \[[@CR15]\] represent a feasible option to treat lesions in the central/motor cortex areas (see Table [1](#Tab1){ref-type="table"}). However, no previous study has directly compared these two modalities to define an optimal treatment regime, in regards to functional outcomes.Table 1Overview of published results of functional outcome of different treatment modalities (MRS vs. SRS/SRT) of brain metastases in the motor cortex regionPatientsTumor volumePreoperative hemiparesisRPA Score meanMotoric improvementMotoric deteriorationWeil RJ et Louser RR ^a^1710.2 cm^3^ (mean)100%1,9288%12%Obermueller T et al. ^a^56--57%231%21%present series MRS ^a^2710.5 cm^3^ (mean)89%1.8554%11%present series SRT/SRS ^b^414.9 cm^3^ (mean)20%1.8117%5%Luther N. et al. ^b^9627 pat. \>9 cm^3^51%--31%37%69 pat. \<9 cm^3^--12%MRS series are marked with ^a^, SRT/SRS series are marked with ^b^

In this study, we retrospectively collected prospective data from patients receiving either microsurgery or stereotactic radiotherapy/radiosurgery from two cooperating regional treatment centers. Eligible patients were identified by searching for central metastasis treatments in a microsurgical register for intraoperative neuromonitoring and in a prospective database for stereotactic radiotherapy/radiosurgery. Both groups were standardized and pooled together for analysis. Potential factors influencing the primary endpoint of "early functional outcome," such as neurological status before treatment, Karnofsky performance index (KPI) \[[@CR16]\], recursive portioning analysis (RPA) score \[[@CR17]--[@CR19]\], histology, tumor localization, and tumor volume were statistically analyzed.

Methods {#Sec2}
=======

Patient populations {#Sec3}
-------------------

Two prospectively documented institutional databases, 1) the register for intraoperative neuromonitoring of the Department for Neurosurgery, University of Bonn Medical Center, and 2) the database for SRT/SRS of the Department for Radiotherapy, the MediClin Robert Janker Clinic (Bonn, Germany), were retrospectively searched for cases of centrally-located cerebral metastases, details of the selection process are presented in the flow chart (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flowchart representing the structure of our selection process for the study collective

We performed a retrospective analysis of 2061 cases of micro-surgically operated patients under electrophysiological control, as well as 428 cases of stereotactic radiotherapy patients during the period of January 2008 to September 2012. The particular form of treatment was decided in a weekly multidisciplinary neuro-oncology tumor board with permanent participation of senior consultants from: the neurosurgery, radiotherapy, neuroradiology, neurooncology/neurology and was conformed to current guidlines for the treatment of cerebral metastases and the latest scientific evidence. In the case of centrally located metastases, the prognosis was initially estimated based on known scores (for example, SIR: \[[@CR20], [@CR21]\], and the less invasive option of stereotactic irradiation was generally used primarily in patients with a survival prognosis of less than half a year. Stereotactic biopsies were not used in this series and in generally only exceptionally in suspected metastases. In the case of an unclear primary or a missing histology, a resection was recommended for histological evaluation. Otherwise the patients were offered both therapy options. After clarification on the advantages and disadvantages of both treatment options, the patients could usually choose which therapy they prefer.

For metastases with a volume of ≤4.5 cm^3^ and a 10 Gy volume of ≤10 cm^3^, a classic one session radiosurgery with a marginal dose of 20 Gy was used. In case of metastases \>4.5 cm^3^ or a 10 Gy volume \> 10 cm^3^, the hypofractionated variant was used (see Table [2](#Tab2){ref-type="table"}).Table 2Overview of the applied radiation modalities, doses and fractions in SRS/SRT in relation to the tumor volumeVolumePatientsPercentage of SRS treatmentsMean SRS dose (Gy)Fractions(mean)Mean SRT dose (Gy)\< 4.5 cm^3^2843%20Gy10.535Gy\> 4.5 cm^3^137%20Gy10.333Gy

MRS was performed over a free craniotomy under general anesthesia with intravenous analgosedation. Intraoperative electrophysiology was used to identify the senso-motoric cortex. MRS was then monitored by somatosensory evoked potential and motoric evoked potentials.

Inclusion/exclusion criteria {#Sec4}
----------------------------

Cerebral metastases located within either the precentral gyrus of the motor cortex, or adjacent to the precentral gyrus in the fronto-dorsal area or the postcentral area, were included for analysis. The motor strip was identified on magnetic resonance imaging (MRI) by using standard anatomical cues, including presence of an "omega sign" in the central sulcus, termination of the superior frontal sulcus into the prefrontal sulcus, and the paracentral lobule located directly anterior to the pars marginalis. In addition, intraoperative and electrophysiologically identified cases using the phase reversal technique were included \[[@CR22], [@CR23]\].

Patients with no follow-up after treatment or with other cerebral metastasis that could affect the motor pathway like basal ganglia, brain stem, and spinal metastases were excluded from this study (see Fig. [1](#Fig1){ref-type="fig"}).

Analysis of motor function {#Sec5}
--------------------------

Motor function was prospectively analyzed and documented both pre- and post-procedure by each department at 1 day before and over 1--3 weeks intervals after either MSR or SRT/SRS. Motor function was graded for all patients according to the BMRC scale \[[@CR11]\], as: normal (5/5); mild weakness (4/5); moderate weakness with the strength to overcome gravity (3/5); weakness with not enough strength to overcome gravity, but with notable movement (2/5); severe weakness with not visually but palpable movement (1/5); and absolute weakness or plegia (0/5). Hemiparesis was defined as a grade lower than 5/5 independent of the underlying reason caused by each technique (edema, hemorrhage, empyema, or collateral damage).

Adverse events {#Sec6}
--------------

Adverse events were retrospectively evaluated and taken in account up to 3 months after the initial therapy, by documentation in patient records or reported by practitioners afterwards. We divided the adverse events into local complications directly associated with the treatment such as bleeding, infection, radio-necrosis, and systemic adverse events not directly associated with the local treatment such as pneumonia, thrombosis, and pulmonary embolism.

Statistical analysis {#Sec7}
--------------------

Univariate and multivariate statistical analyses were performed to determine which patient and tumor-related factors influenced functional outcome. Factors evaluated included tumor volume, patient age, tumor localization, if the tumor directly involved the motor cortex, KPI, dexamethasone daily dose, and preoperative motor deficit. We evaluated the motor function outcome in patients with and without deficits prior to each treatment. As a surrogate parameter for clinically-relevant edema, we examined dexamethasone treatment during follow-up.

These statistical comparisons were analyzed using Fisher's exact test and Student's t-test. Multivariate analyses were performed as binary logistic regression analysis with IBM SPSS Statistics version 20.0 (IBM Corp., North Castle, NY, USA). A *p*-value of *p* ≤ 0.05 was considered statistically significant.

Results {#Sec8}
=======

From both patient databases, a total of 68 patients were identified as meeting the inclusion criteria. Of the 68 total patients, 27 were MSR treatments and 41 were SRT/SRS treatments. However, 2 SRT/SRS cases were missing data and were therefore excluded from further statistical analysis. Moreover, 1 patient had surgical resection with SRT over 3 months later, this patient included in both treatment arms. Regarding pre-operatively assessed variables, the MSR group differed significantly from the SRT/SRS group for tumor volume (10.5 cm^3^ vs. 4.9 cm^3^, *p* = 0.02), rate of preoperative hemiparesis (88.9% vs. 19.5%, *p* = 0.005), and muscle strength of the extremities (lower extremities, 4.3 vs. 4.8, *p* = 0.008; upper extremities, 3.7 vs. 4.7, *p* = 0.0005) according to the BMRC criteria. No significant difference was found between both groups regarding age, gender, primary tumor histology, pre-treatment KPI, and oncological status on the RPA score as shown in detail in Table [3](#Tab3){ref-type="table"}.Table 3Pre-treatment demographics, oncological data, and motor status of patients with central metastasis, based on the treatment modalities, namely, MRS or SRS/SRTOverallMRSSRT/SRS*p*Treatments682741Patients (n)642737Females (%)52%52%52%n.s.Age (years)59.56059n.s.RPA1.831.851.81n.sKPI pre-operative \*788078n.sTumor-Volume (cm^3^) \*7.210.54.9\<0.02Patients with Hemiparesis362412\<0.005Muscle strength (BMRC)\*:Arm4.33.74.7\<0.008Leg4.64.34.8\<0.0005NSCLC43%44.4%42.4%n.sMamma-Ca14.5%18.5%11.9%n.s.Melanoma13%18.5%9.5%n.s.Renal Cell Ca5.8%0%9.5%n.s.CUP5.8%0%9.5%n.s.SCLC4.3%0%7.1%n.sGerm Cell Ca4.3%7.4%2.4%n.s.Gastrointestinal Ca4.3%3.7%4.8%n.s.Urothelial Cell Ca2.9%3.7%2.4%n.s.Sarcoma1.4%3.7%0%n.s.*SRT/SRS* Stereotactic radiotherapy or radiosurgery, *MRS* Microsurgery, *KPI* Karnofsky performance index, *RPA* Recursive partitioning analysis, *BMRC* British Medical Research Council, *NSCLC* Non-small cell lung cancer, *SCLC* small cell lung cancer, *Ca* Carcinoma, *CUP*: Carcinoma of unknown primary, *n.s* not significant\* mean value

When comparing the early postoperative mean muscle strength of the extremities between the MSR and SRT/SRS groups, there was no significant difference in either the upper or lower extremities. However, when considering the rate of improvement, the strength of the lower extremities improved significantly more in the MSR group (by 0.4 points), as compared to no improvement in the SRT/SRS group. Although the improvement of the upper extremities muscle strength was not significant, the MSR patients' strength improved in the upper extremities by 0.4 points as compared to the SRT/SRS group. These details are described in Table [4](#Tab4){ref-type="table"}.Table 4Motor outcomes and complications in patients with central metastasis based on the treatment modalities, namely, MRS vs SRT/SRSOverallMRSSRT/SRS*p*Muscle strength (BMRC)\* Arm4.54.14.7n.s. Leg4.64.44.8n.s.Patients with motor improvements (%)44.8%54.2%16.7%\<0.042Motoric Improvement (BMRC)\* Arm0.50.1n.s. Leg0.40.0\<0.05Motoric Deterioration10.7%11.1%5.1%0.1Dexamethasone daily dose (mg)4.59.5\<0.001Overall complications31.9%25.9%35.7%n.s. Local13%18.5%9.5%n.s. Systemic18.8%7.4%26.2%\<0.06*SRT/SRS* Stereotactic radiotherapy or radiosurgery, *MRS* Microsurgery, *BMRC* British Medical Research Council, *n.s* not significant\* mean value

An overall improvement of a pre-treatment motor deficit in the upper or lower extremity was found significantly more often in MSR patients (54% vs. 17%, *p* = 0.04); this finding was also significant in the multivariate analysis (*p* = 0.05). A localization of the metastasis adjacent to the precentral gyrus revealed a statistical trend to better improvement of the motor deficit only in the multivariate analysis (*p* = 0.067), but was not significant in the univariate analysis (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}).Table 5Multivariate analysis of different influencing factors (in the first column), with the motor outcomes and complications (in the first row)Overall complication rateSystemic complication rateLocal complication rateMotoric improvementMotoric deteriorationDexamethasone daily dosesMRS vs SRS/SRT--*p* \< 0.02 (correlates with SRS/SRT)--*p* \< 0.05 (correlates with MRS)--*p* \< 0.04 (correlates with SRS/SRT)Age--*p*\~0.05 \* (correlates with higher age)--------Tumor Volume----*p* \< 0.03 (correlates with higher volume)--*p* \< 0.01 (correlates with higher volume)--KPI--------*p* \< 0.01 (correlates with lower KPI)--Located at the precentral gyrus vs adjacent to precentral gyrus------*p* \< 0.07 (correlates with location adjacent to precentral gyrus)----Dexamethasone daily doses----------X\* a *p* value that was not constant in the different regression analysis models and x mark a factor of influence which was not taken in account for the regression analysis of this certain outcome. Non-significant *p*-values were marked with (−)*SRT/SRS* Stereotactic radiotherapy or radiosurgery, *MRS* Microsurgery, *KPI* Karnofsky performance index

A statistical trend of a lower rate of motor function deterioration was observed in the SRT/SRS group (4.8% vs. 11.1%, *p* = 0.10). However, this trend could not be confirmed in the multivariate analysis where deterioration of the motor function showed a significant correlation only with tumor volume (*p* = 0.009) and preoperative KPI (*p* = 0.006) (Table [5](#Tab5){ref-type="table"}).

The overall incidence of complication was 25% in the MSR group and 35.7% in the SRT/SRS group, but this difference was not statistically significant (see Table [6](#Tab6){ref-type="table"}). However, when examining specific sites of complication (local vs. systemic), there was a higher but non-significant rate difference of local complications in the MSR group vs. SRT/SRS group (18.5% vs. 9.5%). This was confirmed in binominal regression analysis, where the only determining factor of local complication incidence was tumor volume (*p* = 0.025) (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}).Table 6Overview of local and systemic complications depending the treatment modalityOverallMRSSRT/SRSLocal complications:brain abscess and meningitis22--seizure312bleeding11--wound healing complications11--vigilance disturbance1--1vertigo1--1Systemic complicationspneumonia514lung embolism211candida esophagitis, gastritis4--4psychosis2--2

In the univariate and multivariate analyses of systemic complications, there was a correlation with SRT/SRS (26.2% vs. 7.4%, univariate *p* = 0.06; multivariate *p* = 0.017), but only in some multivariate statistical tests with a higher patient age (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}).

In the SRT/SRS group, the daily dexamethasone dose was significantly higher compared to the MSR group (9.5 mg vs. 4.5 mg, *p* = 0.001); this difference remained significant even if tumor volume, age, KPI, and tumor localization was adjusted (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}).

Discussion {#Sec9}
==========

Advantages and disadvantages of microsurgery {#Sec10}
--------------------------------------------

For treatment with MSR, there seems to be a significant difference regarding the recovery of motor deficits caused by central metastases as compared with SRT/SRS. However, this recovery may also depend on other factors, such as the exact neuroanatomical localization of the metastases. From the standpoint of neurosurgery, it certainly impacts recovery if a metastasis is located either directly in the precentral gyrus or only adjacent to it. In our study, a localization of the metastasis adjacent to the precentral gyrus revealed only a statistical trend toward better improvement of the motor deficit in the multivariate analysis, but not in the univariate analysis.

The electrophysiologically controlled, intra-operative identification of the pyramidal tract is standard practice and was carried out consistently in our study. The pre-operative identification of the pyramidal tract by navigated transcranial magnetic stimulation (nTMS) \[[@CR24]\], is increasingly utilized over the last 5 years, which implies that this technique was not available during the treatment period of our study (2008--2012). If such pre-operative methods can demonstrate that a metastasis grows directly in the pyramidal tract, such critical cases could be excluded early from operation. Alternatively, a calculated hemiparesis risk could be discussed with the patient. Moreover, this could show a reduced quality of life and therefore be declined as a treatment for these patients. These critical patients could then choose SRT/SRS as an alternative treatment.

Due to the invasive nature of MSR, our results demonstrate a higher rate of local complications such as bleeding, infection, or infarction. We believe that the precise preoperative selection of patients with a disposition for local complications is a crucial factor to improve surgical outcomes. This screening should include the exclusion of adverse blood clotting and a comprehensive evaluation of the patient's immune system, which is supported by the neurosurgical literature \[[@CR25]--[@CR27]\]. The reduction of the local complication rate remains vital, as the start of most adjuvant therapy depends on rapid and complete wound healing and recovery post-surgery. In addition, by further improving the MSR technique and intraoperative monitoring, microsurgery should improve in both general and motor deficit outcomes.

A topic we do not assess in our study is local tumor recurrence for each treatment option. Conform to the guidelines for cerebral metastases for all patients a postoperative adjuvant radiation therapy was recommended and performed depending on the postoperative KPI. However, post-op radiation therapy was usually performed with a delay of 2--4 weeks after MSR and we did not assess these data because we focused on the early functional outcome. Recent publications cautioned not to underestimate local recurrence after microsurgery, especially if a supramarginal resection cannot be administered \[[@CR28], [@CR29]\]. This is particularly important in the critical central region, since resection must be conservative in this area of the brain. Microsurgery of cerebral metastases in the Rolandic area may therefore be inferior to local radiotherapy, regarding local tumor recurrence. This inferiority of MSR in comparison to SRT/SRS without adjuvant therapy has been previously described \[[@CR7]\]. By future improvements in adjuvant systemic therapy, the progression-free survival in these cases may be less dependent on whether local therapy utilizes radiotherapy or microsurgery.

Advantages and disadvantages of radiotherapy {#Sec11}
--------------------------------------------

Due to early detection by routine MRI staging, as well as the MRI screening during follow-up, the majority of central metastases may be small and asymptomatic upon discovery. Especially for these types of metastases, SRT/SRS seems to be the optimal choice according to our data. However, treatment of central metastases by SRT/SRS also has some disadvantages. First, SRT/SRS failed to improve motor function in patients with pre-existing motor deficits in our study. Second, and possibly related to the first, SRT/SRS has a significantly higher dose and longer duration of edema therapy, as revealed by administration of dexamethasone (SRT/SRS vs. MSR = 9.5 mg vs. 4.5 mg, *p* = 0.001). The higher and prolonged dexamethasone therapy in SRT/SRS patients may have implications beyond local impact by also having a negative systemic influence. Dexamethasone was individually administered and adapted to the neurological symptomatics (in particular the motoric function) of the patients. The highest daily dose of 24 mg was reduced regularly for about 1--2 weeks. However, the more intense dexamethasone therapy in SRT/SRS patients may be one explanation for the positive correlation between the higher rate of systemic complications with SRT/SRS observed in our study. Therefore, an improvement in edema therapy by reducing dexamethasone dose and the adoption of new molecular anti-edematous treatment approaches, such as anti-VEGF therapy \[[@CR30], [@CR31]\], may improve outcomes for stereotactic radiotherapy of central metastases in the future. Another explanation for the higher prevalence of systemic complications in SRT/SRS patients could be a higher proportion of ill and/or and elderly patients than found in the MSR cohort. In our study, however, there were no significant differences concerning age and KPI, with only a weak correlation between systemic complications and age in the multivariate analysis. Another key factor for improvement in the treatment outcomes of stereotactic radiotherapy could be the optimization of radiotherapy fractionation, single fraction versus hypofractionation, to reduce the rate of radiogenic edema and necrosis. The tumor volume dependence of radio-necrosis has been proven in stereotactic radiosurgery \[[@CR32]\]. Hypofractionated stereotactic techniques are increasingly used as an alternative option in cases with a large treatment volume, in an effort to protect the surrounding normal tissue \[[@CR33]\].

Statistics and Limitations {#Sec12}
--------------------------

Our study had some limitations. The results of this study should be interpreted with caution, due to its retrospective design. We are aware of the differences regarding tumor size and motor deficits before treatment and made efforts to taken them into account in the statistical analyses. We considered only the restricted collective with motor deficits before treatment concerning the calculation of improvement of motor deficits. In addition, we controlled all our univariate results by multivariate regression analyses. Moreover, there is a patient selection bias due to the guidelines for SRS, which usually restricts treatment to tumor sizes smaller than 2.5 cm in diameter, or 4.5 cm^3^ in volume. Despite this selections bias, we consider our results a valuable contribution, since they emphasize an often overlooked outcome parameter for the treatment of cerebral metastases, which is very important for patient quality of life: the motor function and a method to quantify and evaluate this important neurological function.

Future perspective {#Sec13}
------------------

As cancer becomes more a chronic disease \[[@CR1]--[@CR3]\], central cerebral metastases may become more common. As a result, neurological functional outcome may gain clinical importance in the future, in addition to oncological outcomes \[[@CR4]--[@CR6]\]. New imaging techniques may improve the detection and the resolution of metastases and the surrounding structures. This is important for the neuronavigation in microsurgery and for the target volume defined for radiotherapy. Moreover, these diagnostic techniques might be able to give molecular properties, which can be taken into consideration for future treatment decisions. Furthermore, new bio-molecular drugs \[[@CR30], [@CR31]\] and bio-molecular materials \[[@CR34]\], may improve the overall oncological outcomes, as well as control the side effects of both microsurgery \[[@CR34]--[@CR36]\] and stereotactic radiotherapy \[[@CR37]\] in the future.

Conclusions {#Sec14}
===========

To the best of our knowledge, this is the first report to compare the two standard treatment options, MRS and SRT/SRS, of central cerebral metastases by examining their functional outcome and risk profile. Our data showed that the presence of a pre-operative motor deficit, as well as the tumor volume, should be taken in consideration when deciding the treatment modality. However, since microsurgical resection remains an invasive therapy, evaluation of the patient's blood clotting function and the immune system, should be considered for reducing complications in microsurgery.

BMRC

:   British Medical Research Council

MRI

:   Magnetic resonance imaging

MSR

:   Microsurgical resection

SRS

:   Stereotactic radiosurgery

SRT

:   Stereotactic radiotherapy

We appreciate the efforts, the time, and the contributions of all investigators and medical staff who were involved in the complex therapies. Gratitude is expressed to all patients.

Competing interests: {#FPar1}
====================

No competing interest concerning all authors.

Funding {#FPar2}
=======

The study was not specifically funded.

Availability of data and materials {#FPar3}
==================================

All statistical results are presented as tables in the manuscript.

JPB and BP drafted and edited the manuscript. JPB maintained the SRT/SRS database and YP the intraoperative neuromonitoring database. BP collected the data and performed the statistics. BB, TMK and KG revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar4}
==========================================

The authors confirm that the approval of an institutional review board was not required for this study, because of its retrospective manner.

Consent for publication {#FPar5}
=======================

The publication contains no individual person's data in any form (including individual details, images or videos).

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
